SCHEMBL3344975

SCHEMBL3344975

CSCOc1cc(Cl)c(-c2noc(-c3cn4cc(C(F)(F)F)cc(Cl)c4n3)n2)cc1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.43
NPC1 O15118 4/20 0.43
NFKB1 P19838 4/20 0.43
RAB9A P51151 4/20 0.43
NFKB2 Q00653 4/20 0.43
RELA Q04206 4/20 0.43
KDM4E B2RXH2 1/20 0.43
ALDH1A1 P00352 1/20 0.43
TDP1 Q9NUW8 1/20 0.43
MAPT P10636 3/20 0.42
LMNA P02545 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
RECQL P46063 1/20 0.41
PKM P14618 1/20 0.39
CNR2 P34972 2/20 0.33
S1PR1 P21453 3/20 0.32
SUV39H2 Q9H5I1 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3342896 0.88 SMN1; SMN2 (0.46) SMN1; SMN2NPC1NFKB1RAB9ANFKB2
SCHEMBL2501702 0.88 SMN1; SMN2 (0.43) SMN1; SMN2NPC1NFKB1RAB9ANFKB2
SCHEMBL3340971 0.87 SMN1; SMN2 (0.53) SMN1; SMN2NPC1NFKB1RAB9ANFKB2
SCHEMBL3341427 0.87 SMN1; SMN2 (0.43) SMN1; SMN2NPC1NFKB1RAB9ANFKB2
SCHEMBL3340818 0.87 SMN1; SMN2 (0.43) SMN1; SMN2NPC1NFKB1RAB9ANFKB2
SCHEMBL3341142 0.87 SMN1; SMN2 (0.43) SMN1; SMN2NPC1NFKB1RAB9ANFKB2
SCHEMBL2502466 0.86 NPC1 (0.45) SMN1; SMN2NPC1NFKB1RAB9ANFKB2
SCHEMBL3343941 0.86 SMN1; SMN2 (0.42) SMN1; SMN2NPC1NFKB1RAB9ANFKB2
SCHEMBL2499294 0.86 SMN1; SMN2 (0.42) SMN1; SMN2NPC1NFKB1RAB9ANFKB2
SCHEMBL3340963 0.86 NPC1 (0.42) SMN1; SMN2NPC1NFKB1RAB9ANFKB2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using EXELIXIS, INC. (US) 2010-06-24 US disclosed
WO-2010065760-A1 IMIDAZO [1,2A] PYRIDINE DERIVATIVES, THEIR USE AS S1P1 AGONISTS AND METHODS FOR THEIR PRODUCTION EXELIXIS, INC. (US) 2010-06-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160369-A1 S1P1 Agonists and Methods of Making And Using S1PR1, S1PR5, S1PR3 SMN1; SMN2 2046/4885NPC1 241/4885NFKB1 3452/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.